Sažetak
Background:Empyema is an infectious disease characterized by the accumulation of pus in the pleural space and accompanied by inflammation. Patients often present with fever, chest pain, dyspnea, or cough, and delayed diagnosis or treatment is associated with high mortality rates. Therefore, in this study, we aim to investigate the clinical utility of the Systemic Inflammation Response Index (SIRI), Pan-Immune Value (PIV), C-Reactive Protein (CRP)-Albumin-Lymphocyte (CALLY) index, and Systemic Immune-Inflammation Index (SII) in assessing the severity of empyema and predicting mortality risk.
Methods:Between January 2022 and October 2024, 73 patients diagnosed with empyema in the thoracic surgery clinic were included in the study. Patients were categorized based on the need for intensive care. Demographic and laboratory data (e.g., white blood cell count, platelet count, albumin levels, pleural fluid culture results, and C-reactive protein levels) were recorded. Differences between empyema patient groups, classified according to disease severity, were analyzed.
Results:Among the 73 patients included in our study, 4 deaths were recorded. It was observed that the CALLY index could be used for intensive care and ward triage (p:0.039). While the SII and SIRI indices were not suitable for triage purposes, the SIRI index was found to be useful for predicting mortality (p:0.01).
Conclusion:In empyema cases, the CALLY index can be used to determine the need for intensive care, while the SIRI index can help predict mortality risk.
Ključne reči
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.